Erratum to: Safety and Efficacy of Gevokizumab in Patients with Behçet’s Disease Uveitis: Results of an Exploratory Phase 2 Study (Ocular Immunology & Inflammation, (2017), 25, 1, (62–70), 10.3109/09273948.2015.1092558);Safety and Efficacy of Gevokizumab in Patients with Behçet’s Disease Uveitis: Results of an Exploratory Phase 2 Study

Ocular Immunology and Inflammation

Volumn 25, Issue 1, 2017, Pages 62-70

  Tugal Tutkun, Ilknur ^a   Kadayifcilar, Sibel ^b   Khairallah, Moncef ^c   Lee, Sung Chul ^d   Ozdal, Pinar ^e   Özyazgan, Yilmaz ^f   Song, Ji Hun ^g   Yu, Hyeong Gon ^h   Lehner, Valerie ⁱ   de Cordoue, Agnès ⁱ   Bernard, Oana ⁱ   Gül, Ahmet ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

^c FATTOUMA BOURGUIBA UNIVERSITY HOSPITAL   (Tunisia)

^d Yonsei University College of Medicine   (South Korea)

^e Ulucanlar Eye Research Hospital   (Turkey)

^f ISTANBUL UNIVERSITY   (Turkey)

^g Ajou University School of Medicine   (South Korea)

^h Seoul National University College of Medicine   (South Korea)

ⁱ IRIS Institut de Recherches Internationales Servier   (France)

Author keywords

Beh et s disease; gevokizumab; interleukin 1 beta; retinal vasculitis; uveitis

Indexed keywords

GEVOKIZUMAB; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE; GLUCOCORTICOID; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BEHCET DISEASE; CATARACT; CATARACT EXTRACTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; ECG ABNORMALITY; EXPLORATORY RESEARCH; FEMALE; GLAUCOMA; HEADACHE; HUMAN; HYPERTENSION; MACULAR EDEMA; MALE; MYALGIA; OPTIC NERVE ATROPHY; OROPHARYNX PAIN; PARS PLANA VITRECTOMY; PHASE 2 CLINICAL TRIAL; PHEOCHROMOCYTOMA; PROSPECTIVE STUDY; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; RETINA DISEASE; RETINAL INFILTRATE; TOOTH ABSCESS; TRABECULECTOMY; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; UVEITIS; VASCULITIS; VITREOUS HEMORRHAGE; VOLUME OF DISTRIBUTION; BEHCET SYNDROME; CLINICAL TRIAL; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; VISUAL ACUITY;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; BEHCET SYNDROME; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY;

EID: 84958040105     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.1080/09273948.2017.1355174     Document Type: Erratum

References (18)

1. Sakane T, Takeno M, Suzuki N, et al. Behcet’s disease. N Engl J Med. 1999;341:1284–1291.
2. Hatemi G, Yazici Y, Yazici H., Behcet’s syndrome. Rheum Dis Clin North Am. 2013;39:245–261.
3. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, et al. Uveitis in Behcet disease:an analysis of 880 patients. Am J Ophthalmol. 2004;138:373–380.
4. Hatemi G, Silman A, Bang D, et al. EULAR recommendations for the management of Behcet disease. Ann Rheum Dis. 2008; 67:1656–1662.
5. Owyang AM, Issafras H, Corbin J, et al. XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1beta-mediated diseases. MAbs. 2011;3:49–60.
6. Roell MK, Issafras H, Bauer RJ, et al. Kinetic approach to pathway attenuation using XOMA 052, a regulatory therapeutic antibody that modulates interleukin-1beta activity. J Biol Chem. 2010;285:20607–20614.
7. Issafras H, Corbin JA, Goldfine ID, et al. Detailed mechanistic analysis of gevokizumab, an allosteric anti-IL-1beta antibody with differential receptor-modulating properties. J Pharmacol Exp Ther. 2014;348:202–215.
8. Gul A, Tugal-Tutkun I, Dinarello CA, et al. Interleukin-1beta-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet’s disease:an open-label pilot study. Ann Rheum Dis. 2012;71:563–566.
9. International Study Group for Behcet’s Disease. Criteria for diagnosis of Behcet’s disease. Lancet. 1990;335:1078–1080.
10. Jabs DA, Nussenblatt RB, Rosenbaum JT., Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140:509–516.
11. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol. 1985;103:1796–1806.
12. BenEzra D, Forrester JV, Nussenblatt RB, et al. Uveitis Scoring System. Berlin, Germany:Springer Verlag; 1991.
13. Tugal-Tutkun I, Herbort CP, Khairallah M., Scoring of dual fluorescein and ICG inflammatory angiographic signs for the grading of posterior segment inflammation (dual fluorescein and ICG angiographic scoring system for uveitis). Int Ophthalmol. 2010;30:539–552.
14. Mizushima Y, Inaba G, Mimura Y., Guide for Diagnosis of Behcet’s Disease, Behcet’s Diesase Research Committee, Japan. Tokyo, Japan:Ministry of Health and Welfare; 1987.
15. Lachmann HJ, Quartier P, So A, et al. The emerging role of interleukin-1beta in autoinflammatory diseases. Arthritis Rheum. 2011;63:314–324.
16. Sfikakis PP, Theodossiadis PG, Katsiari CG, et al. Effect of infliximab on sight-threatening panuveitis in Behcet’s disease. Lancet. 2001;358:295–296.
17. Cavelti-Weder C, Babians-Brunner A, Keller C, et al. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care. 2012; 35:1654–1662.
18. Gul A., Standard and novel therapeutic approaches to Behcet’s disease. Drugs. 2007; 67:2013–2022.